Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 30, 2016 07:30 ET | Source: Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals Announces Acceptance of Abstracts for EASL Meeting

- Late Breaker Oral Presentation of Phase 2 Liver Cirrhosis Trial Three-month Data - - Poster of Preclinical Data Addressing Safety of Caspase Inhibition in Cancer Treatment - SAN DIEGO, March ...
March 09, 2016 16:05 ET | Source: Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals Reports 2015 Financial Results and Program Updates

SAN DIEGO, March 09, 2016 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver...
March 02, 2016 07:01 ET | Source: Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals to Report Fourth Quarter and Full Year 2015 Financial Results

SAN DIEGO, March 02, 2016 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver...
February 03, 2016 07:30 ET | Source: Conatus Pharmaceuticals Inc.

FDA Grants Conatus Fast Track Designation for Development of Emricasan in NASH Cirrhosis

SAN DIEGO, Feb. 03, 2016 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the...
February 02, 2016 07:30 ET | Source: Conatus Pharmaceuticals Inc.

Conatus to Present at BIO CEO & Investor Conference

SAN DIEGO, Feb. 02, 2016 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced its scheduled presentation to provide an overview of the company’s programs and outlook at...
January 11, 2016 07:30 ET | Source: Conatus Pharmaceuticals Inc.

Conatus Initiates Phase 2b ENCORE-NF Clinical Trial of Emricasan in Patients With NASH Fibrosis

SAN DIEGO, Jan. 11, 2016 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced the initiation of active patient recruitment in ENCORE-NF, a randomized, double-blind,...
January 05, 2016 16:05 ET | Source: Conatus Pharmaceuticals Inc.

Conatus Achieves Positive Results with Emricasan in Initial Stage of Phase 2 Liver Cirrhosis Clinical Trial

- Consistent Treatment Effect Observed on Biomarkers in Overall Patient Population - - Emricasan Improves Key Measures of Liver Function in High Medical Need Subgroup - - Conference Call and...
November 16, 2015 16:30 ET | Source: Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals Announces Late-Breaking Oral Presentation at AASLD Annual Meeting

- Results From Multicenter Phase 2 Portal Hypertension Clinical Trial in Patients With Liver Cirrhosis - - Emricasan Significantly Lowered Portal Pressure in Patients With Severe Portal...
November 16, 2015 11:00 ET | Source: Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals Announces Poster Presentations at AASLD Annual Meeting

- Caspase Inhibition Suppresses Production of Biologically Active Microparticles in Murine Model of Alcoholic Liver Disease - - Emricasan Improves Survival and Portal Hypertension in Murine Model...
November 14, 2015 12:00 ET | Source: Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals Announces Selection of Late-Breaking Oral Presentation as Noteworthy Abstract to be Highlighted in AASLD President's Press Conference at AASLD Annual Meeting

SAN DIEGO, Nov. 14, 2015 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) announced today that the company's late-breaking oral presentation at The Liver Meeting®, the annual...